A detailed history of Jpmorgan Chase & CO transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 16,703 shares of RAPT stock, worth $17,872. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,703
Previous 16,573 0.78%
Holding current value
$17,872
Previous $50,000 34.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$1.76 - $3.75 $228 - $487
130 Added 0.78%
16,703 $33,000
Q2 2024

Aug 12, 2024

SELL
$2.89 - $9.38 $8,302 - $26,948
-2,873 Reduced 14.77%
16,573 $50,000
Q1 2024

May 10, 2024

SELL
$6.87 - $26.45 $46,633 - $179,542
-6,788 Reduced 25.87%
19,446 $174,000
Q4 2023

Feb 12, 2024

SELL
$11.28 - $25.46 $1,838 - $4,149
-163 Reduced 0.62%
26,234 $651,000
Q3 2023

Nov 14, 2023

BUY
$16.34 - $24.66 $32,418 - $48,925
1,984 Added 8.13%
26,397 $438,000
Q2 2023

Aug 11, 2023

SELL
$16.06 - $21.61 $2,826 - $3,803
-176 Reduced 0.72%
24,413 $456,000
Q1 2023

May 18, 2023

BUY
$17.19 - $30.8 $392,722 - $703,656
22,846 Added 1310.73%
24,589 $451,000
Q1 2023

May 11, 2023

SELL
$17.19 - $30.8 $253,432 - $454,084
-14,743 Reduced 89.43%
1,743 $31,000
Q4 2022

Feb 13, 2023

BUY
$16.28 - $24.6 $1,155 - $1,746
71 Added 0.43%
16,486 $326,000
Q3 2022

Nov 14, 2022

BUY
$17.96 - $30.46 $16,990 - $28,815
946 Added 6.12%
16,415 $395,000
Q2 2022

Aug 11, 2022

BUY
$10.26 - $23.59 $19,432 - $44,679
1,894 Added 13.95%
15,469 $283,000
Q1 2022

May 11, 2022

BUY
$17.02 - $40.22 $44,234 - $104,531
2,599 Added 23.68%
13,575 $299,000
Q4 2021

Feb 10, 2022

SELL
$29.5 - $39.5 $209,627 - $280,687
-7,106 Reduced 39.3%
10,976 $403,000
Q3 2021

Nov 12, 2021

BUY
$29.86 - $39.47 $539,928 - $713,696
18,082 New
18,082 $561,000

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $31.7M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.